Paciclovir is the first COVID-19 drug to be taken orally, and has obtained the emergency use authorization (EUA) from the US Food and Drug Administration (FDA). It is suitable for adults in mild to moderate COVID-19 and/or children aged 0/2 and above weighing at least 40kg.
Paxlovid is an oral drug developed by Pfizer to treat COVID-19. Its main function is to relieve the symptoms of COVID-19 infection and reduce the mortality rate. Paciclovir is mainly composed of two drugs, one is nimatvir and the other is ritonavir.
The combination of these two drugs can prevent the virus from entering infected cells, thus effectively treating COVID-19. In the United States, Paxlovid has been approved by FDA for emergency treatment and can be used to treat COVID-19.
Palovir is a therapeutic drug for COVID-19 developed and produced in Pfizer, USA. At the end of 20021,it was granted emergency authorization by the US Drug Administration (FDA). In March 2022, it was approved to be listed by China National Medical Products Administration and included in medical insurance.
Paciclovir is administered as follows:
Paciclovir is an oral drug, with 56 tablets per box, and each tablet contains 300 mg of nemadevir and 0/00 mg of ritonavir/kloc. It is recommended to use paciclovir under the guidance of a doctor before use.
Treatment should be started within 3 days after coronavirus pneumonia-19 infection. Early treatment is helpful to relieve the symptoms of viral infection, reduce the risk of disease deterioration and improve the cure rate. It is recommended to take orally after meals, because eating with meals can help reduce the side effects of gastrointestinal discomfort and improve the absorption rate of drugs.
In clinical trials, Paxlovid has been proved to be effective for people aged 65,438+08 and above who are severe, mild, asymptomatic and immunocompromised, but whether it is safe for pregnant and lactating women has not been determined.
It should be noted that the evaluation and diagnosis must be completed under the guidance of a doctor before using paciclovir, and a personalized treatment plan should be formulated according to the patient's specific situation and curative effect. At the same time, the method and time of administration must be strictly observed to ensure the efficacy and safety of paciclovir.